CERTARA INC (CERT) Stock Price, Forecast & Analysis
NASDAQ:CERT • US15687V1098
CERT Key Statistics, Chart & Performance
The current stock price of CERT is 6.46 USD. In the past month the price decreased by -36.1%. In the past year, price decreased by -50.95%.
CERT Technical Analysis
CERT Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to CERT. Both the profitability and the financial health of CERT get a neutral evaluation. Nothing too spectacular is happening here.
CERT Financial Highlights
Over the last trailing twelve months CERT reported a non-GAAP Earnings per Share(EPS) of 0.5. The EPS increased by 28.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.62% | ||
| ROA | 0.71% | ||
| ROE | 1.02% | ||
| Debt/Equity | 0.27 |
CERT Forecast & Estimates
20 analysts have analysed CERT and the average price target is 12.62 USD. This implies a price increase of 95.39% is expected in the next year compared to the current price of 6.46.
For the next year, analysts expect an EPS growth of 1.53% and a revenue growth 8.97% for CERT
CERT Ownership
CERT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 20.59 | 30.011B | ||
| WAY | WAYSTAR HOLDING CORP | 15.18 | 4.934B | ||
| DOCS | DOXIMITY INC-CLASS A | 14.59 | 4.66B | ||
| HTFL | HEARTFLOW INC | N/A | 2.043B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | 231.02 | 1.094B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.093B | ||
| SDGR | SCHRODINGER INC | N/A | 875.817M | ||
| TDOC | TELADOC HEALTH INC | N/A | 865.468M | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 5.6 | 801.055M |
Related stock screener links
View all stocks in the Health Care Technology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CERT
Company Profile
Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. The company is headquartered in Radnor, Pennsylvania and currently employs 1,487 full-time employees. The company went IPO on 2020-12-11. The company accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. The company delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. The company offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
Company Info
CERTARA INC
4 Radnor Corporate Center, Suite 350
Radnor PENNSYLVANIA 08540 US
CEO: William F. Feehery
Employees: 1517
Phone: 18009279800
CERTARA INC / CERT FAQ
What does CERT do?
Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. The company is headquartered in Radnor, Pennsylvania and currently employs 1,487 full-time employees. The company went IPO on 2020-12-11. The company accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. The company delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. The company offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
What is the stock price of CERTARA INC today?
The current stock price of CERT is 6.46 USD. The price decreased by -2.86% in the last trading session.
What is the dividend status of CERTARA INC?
CERT does not pay a dividend.
What is the ChartMill rating of CERTARA INC stock?
CERT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What do analysts say about CERTARA INC (CERT) stock?
20 analysts have analysed CERT and the average price target is 12.62 USD. This implies a price increase of 95.39% is expected in the next year compared to the current price of 6.46.
What is the Price/Earnings (PE) ratio of CERTARA INC (CERT)?
The PE ratio for CERTARA INC (CERT) is 12.92. This is based on the reported non-GAAP earnings per share of 0.5 and the current share price of 6.46 USD.
Is CERTARA INC (CERT) expected to grow?
The Revenue of CERTARA INC (CERT) is expected to grow by 8.97% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.